MetaCap

Enlivex (ENLV) vs Genprex (GNPX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enlivex is the larger company by market cap ($2.0 million vs $1.9 million), about 1.0 times the size. On valuation, Enlivex trades at a lower trailing P/E (0.0x vs 0.0x for Genprex).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%GNPX-44.66%
+823%+367%-88%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%GNPX-46.69%
+633%+277%-79%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus GNPX key metrics
MetricENLVGNPX
Share price$1.05$1.45
Market cap$2.01M$1.94M
1-day change-11.76%-13.17%
P/E ratio (TTM)0.000.01
EPS (TTM)$7,904.00$98.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B$-16.23M
52-week high$434.40$80.96
52-week low$1.00$1.45
Distance from 52-week high-99.76%-98.21%
Analyst consensusnone—
Avg. price target upside+7519.05%—
Average volume73.14K168.88K
Shares outstanding1.91M1.33M
Employees3413
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Genprex trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Genprex

GNPX stock →

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

ENLV vs GNPX FAQ

Which is bigger, Enlivex or Genprex?

Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.94M for Genprex (GNPX).

Which has the lower P/E ratio, ENLV or GNPX?

ENLV has the lower trailing P/E at 0.0, versus 0.0 for GNPX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Enlivex and Genprex in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons